Overview

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ado-Trastuzumab Emtansine
Maytansine
Trastuzumab